The Hidden Mental Health Risks of Popular Weight-Loss Medications

A large-scale study has found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like Wegovy and Ozempic may significantly increase the risk of depression, anxiety, and suicidal behavior in patients with obesity. Key findings include:

📊 Risks Associated with GLP-1 RAs:

• 195% higher risk of major depression

• 108% higher risk of anxiety

• 106% higher risk of suicidal ideation/attempts

⏳ Longer Use = Higher RiskThe risks grow with prolonged use, especially with higher doses like Wegovy (Semaglutide 2.4 mg).

⚠️ Who's Most Affected?

• Women and younger adults (18–49) face the highest risks.

• Black patients showed the greatest risk for anxiety and suicidal ideation.

🧠 Why?

GLP-1 RAs might affect dopamine regulation in the brain, disrupting mood and mental health.

👩‍⚕️ What You Should Do:

If you're using or considering GLP-1 RAs for weight management, talk to your doctor about your mental health history and any potential risks. 💬

This study highlights the need for careful evaluation and further research to ensure these medications are used safely.

🔗 Kornelius, E., et al., The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific Reports, 2024. 14(1): p. 24433.

#MentalHealth #ObesityTreatment #HealthRisks #Wegovy #Ozempic #WellnessMatters